Additionally, for the expression of activation and maturation markers among the severe or mild lung impairment groups, we observed that only the frequency of MTB-specific CD4+ T-cells expressing HLA-DR among subjects with mild lung impairment did not significantly change over 6 months of TB treatment (median: 13.85% [IQR: 3.08–28.53%] at baseline to 4.43% [IQR: 1.25%–7.72%] at month 6, p = 0.10). This evidence concerns the gene CD4 and tuberculosis.